BackgroundTo date. the non-viral vector Chimeric Antigen Receptor (CAR) T cell preparation platform. exemplified by transposons. has demonstrated significant potential in tumor immunotherapy and yielded positive results in multiple clinical trials. https://fitnessgravesyardes.shop/product-category/brake/